Barakat Pharmaceutical Group

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
星期一, 十二月 19, 2022

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.

Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth

Retrieved on: 
星期四, 一月 5, 2023

NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.

Key Points: 
  • NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.
  • (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board.
  • “We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,”  stated Hestia Insight’s CEO and Chairman, Edward Lee.
  • We look forward to utilizing Dr. Chaung’s impressive background and skill set to assist with the growth of Hesta Insight.”

Galapagos announces changes to Executive Committee

Retrieved on: 
星期四, 十二月 22, 2022

Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023.

Key Points: 
  • Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023.
  • Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022.
  • He will stay with Galapagos until 31 May 2023 to ensure a smooth transition.
  • The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee.

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

Retrieved on: 
星期五, 十一月 4, 2022

Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.

Key Points: 
  • Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.
  • Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization.
  • Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company.
  • Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares.

Johnson & Johnson’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022

Retrieved on: 
星期一, 七月 18, 2022

Ms. Forminard will also be appointed as a member of Johnson & Johnsons Executive Committee, effective October 17, 2022.

Key Points: 
  • Ms. Forminard will also be appointed as a member of Johnson & Johnsons Executive Committee, effective October 17, 2022.
  • Mr. Ullmann and Ms. Forminard will work together during a transition period until Mr. Ullmanns retirement at the end of this year.
  • I thank him for his unwavering commitment to help deliver on Our Purpose of advancing health for humanity, said Joaquin Duato, Chief Executive Officer, Johnson & Johnson.
  • Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

Retrieved on: 
星期二, 十月 26, 2021

(TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter Solasia) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter this agreement).

Key Points: 
  • (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter Solasia) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter this agreement).
  • Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL).
  • Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan.
  • Nippon Kayaku has contributed to realizing a sustainable society through its four businesses of Functional Chemicals, Pharmaceuticals, Safety Systems, and Agrochemicals.